[Endothelium pharmacology in pulmonary hypertension].
The dysfunction of lung endothelium is crucial in the development of pulmonary hypertension. Dysfunction of endothelial synthesis of prostacyclin (PGI2) and nitric oxide (NO) and increased activity of endothelin 1 (ET-1) are connected to the progress of the disease. In this review the authors describe three major mediators of pulmonary endothelium: NO, PGI2 and ET-1. Their role in pulmonary hypertension and possibilities of pharmacological modulation of their activity are also discussed.
Zakład Farmakodynamiki, Katedra Farmakodynamiki, Collegium Medicum, Uniwersytet Jagielloński, Kraków.
Andrzej
A
Fedorowicz
Stefan
S
Chłopicki
D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D018450:Disease Progression; D019332:Endothelin-1 / Q000378:metabolism; D004727:Endothelium / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009569:Nitric Oxide / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D019332:Endothelin-1; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; D011464:Epoprostenol